Mycovia Pharmaceuticals, Inc.

Viamet Pharmaceuticals, Inc.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Dow Agrosciences LLC

Nqp 1598, Ltd.

Phasebio Pharmaceuticals, Inc.

Vps-3, Inc.

Corxel Pharmaceuticals Hong Kong Limited

Selenity Therapeutics (bermuda), Ltd.

Eikonizo Therapeutics, Inc.

Ji Xing Pharmaceuticals Hong Kong Limited

Viamet Pharmaceuticals (bermuda), Ltd.

Innocrin Pharmaceuticals, Inc.

Christopher M Yates

William Joel Hoekstra

Michael R Loso

Michael Thomas Sullenberger

Asaf Alimardanov

Mark Behnke

Scott A David

Douglas Franklin Fry

Gary David Gustafson

Robert J Schotzinger

Zachary A Buchan

Steven Sparks

Sammy Ray Shaver

Stephen William Rafferty

Maurice C Yap

David Dale Wirth

Asako Kubota

Kimberly M Steward

Eduard Hartmann

Martin F Bindl

Kimberly Deneen Steward

Javier Delgado

Xuelin Wang

Sammy R Shaver

Willam J Hoekstra

Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders, or symptoms thereof mediated by such metalloenzymes. In some embodiments, a provided compound is a compound of Formula I, or a pharmaceutically acceptable salt thereof. In some embodiments, a provided method is a method of alleviating or abating a disorder or disease associated with aldosterone synthase (CYP11B2) or ameliorating a symptom thereof.

Metalloenzyme inhibitor compounds

Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.

Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

The present invention relates to compounds of Formula (I): wherein Ris as defined herein, or an acceptable salt, solvate, prodrug or hydrate thereof. The compounds of Formula I are inhibitors of metalloenzymes, such as lanosterol demethylase (CYP51). 

Antifungal compounds

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders, or symptoms thereof mediated by such metalloenzymes.

The present invention relates to a process for preparing a compound of 5 or 5*, or a mixture thereof, that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compounds 7 or 7* and 11 or 11* and substituted derivatives thereof.

Antifungal compound process

The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.

The present invention relates to a process for preparing a compound of 5 or 5*, or a mixture thereof, and/or a compound of 14 or 14*, or a mixture thereof, that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compounds 7, 7* and 11, 11* and substituted derivatives thereof.

The present invention relates to a process for preparing a compound of 5 or 5*, or a mixture thereof, that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compounds 7, 7* and 11, 11* and substituted derivatives thereof.

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

Growing community of inventors

Raleigh, NC, United States of America

Christopher M Yates